Generics now control the semaglutide market worldwide, pushing brand‑name sales into a narrower niche. Industry trackers note that after a steep rise in India, sales of generic weight‑loss drugs have stabilised and overall demand has stabilised. Recent research finds the drug’s weight‑loss effect fluctuates widely between users, with some seeing strong results and others modest change. Novo Nordisk announced a partnership with Vivani to create a long‑acting semaglutide implant that could release the drug over a few months. The development aims to give the company a additional option as generic competitors capture more of the market. Analysts say the implant could reshape treatment patterns if clinical trials confirm its safety.